

On the Horizon Rx

a Humana Healthy Horizons
newsletter for pharmacy providers

Volume III



Updates made to the 2024 preferred drug list

Humana's Pharmacy and Therapeutics (P&T) committee establishes and maintains the South Carolina Medicaid Preferred Drug List (PDL). The committee met in September 2023 and approved PDL changes that went into effect Jan. 1, 2024. Members were notified of negative changes at least 30 days before the effective date.

Impacted Medicine	Alternative Medicine
Acebutolol 200 mg capsule	Propranolol tablet, metoprolol tartrate tablet, metoprolol succinate ER tablet, extended release 24 hour
Acebutolol 400 mg capsule	Propranolol tablet, metoprolol tartrate tablet, metoprolol succinate ER tablet, extended release 24 hour
Aimovig Autoinjector 140 mg/mL subcutaneous auto-injector	Emgality Pen 120 mg/mL subcutaneous pen injector, Emgality 120 mg/mL subcutaneous syringe
Aimovig Autoinjector 70 mg/mL subcutaneous auto-injector	Emgality Pen 120 mg/mL subcutaneous pen injector, Emgality 120 mg/mL subcutaneous syringe
Aprepitant 125-80-80 mg pack	Aprepitant 80 mg capsules, aprepitant 125 mg capsule
Armour Thyroid 120 mg tablet	Levothyroxine tablet, Euthyrox tablet, NP Thyroid tablet
Armour Thyroid 15 mg tablet	Levothyroxine tablet, Euthyrox tablet, NP Thyroid tablet
Armour Thyroid 180 mg tablet	Levothyroxine tablet, Euthyrox tablet, NP Thyroid tablet
Armour Thyroid 240 mg tablet	Levothyroxine tablet, Euthyrox tablet, NP Thyroid tablet

Humana
Healthy Horizons[®]
in South Carolina

Healthy Connections 

Humana Healthy Horizons in South Carolina is a Medicaid product of Humana Benefit Plan of South Carolina Inc.

414802SC0224

/SCHM7JEEN0224

Impacted Medicine	Alternative Medicine
Armour Thyroid 30 mg tablet	Levothyroxine tablet, Euthyrox tablet, NP Thyroid tablet
Armour Thyroid 300 mg tablet	Levothyroxine tablet, Euthyrox tablet, NP Thyroid tablet
Armour Thyroid 60 mg tablet	Levothyroxine tablet, Euthyrox tablet, NP Thyroid tablet
Armour Thyroid 90 mg tablet	Levothyroxine tablet, Euthyrox tablet, NP Thyroid tablet
Aubagio 14 mg tablet	Teriflunomide tablet, glatiramer subcutaneous syringe, dimethyl fumarate capsule, delayed release
Aubagio 7 mg tablet	Teriflunomide tablet, glatiramer subcutaneous syringe, dimethyl fumarate capsule, delayed release
Balcoltra 0.1 mg-0.02 mg (21)/iron (7) tablet	Consult your physician
BD Insulin Syringe 1 ml 25GX1"	BD Insulin Syringe Ultra-Fine, BD Veo Insulin Syringe Ultra-Fine
BD Insulin Syringe 1 ml 25GX5/8"	BD Insulin Syringe Ultra-Fine, BD Veo Insulin Syringe Ultra-Fine
BD Insulin Syringe 1 ml 26GX1/2"	BD Insulin Syringe Ultra-Fine, BD Veo Insulin Syringe Ultra-Fine
BD Insulin Syringe 0.3 ml 29 gauge x 1/2"	BD Insulin Syringe Ultra-Fine, BD Veo Insulin Syringe Ultra-Fine
BD Insulin Syringe 1 ml	BD Insulin Syringe Ultra-Fine, BD Veo Insulin Syringe Ultra-Fine
BD Insulin Syringe 1 ml 27 gauge x 1/2"	BD Insulin Syringe Ultra-Fine, BD Veo Insulin Syringe Ultra-Fine
BD Insulin Syringe 1 ml 28 gauge x 1/2"	BD Insulin Syringe Ultra-Fine, BD Veo Insulin Syringe Ultra-Fine
BD Insulin Syringe 1 ml 29 gauge x 1/2"	BD Insulin Syringe Ultra-Fine, BD Veo Insulin Syringe Ultra-Fine
BD Insulin Syringe Micro-Fine 1 ml 28 gauge x 1/2"	BD Insulin Syringe Ultra-Fine, BD Veo Insulin Syringe Ultra-Fine
BD Lo-Dose Syringe Micro-Fine IV 1/2 ml 28 gauge x 1/2"	BD Insulin Syringe Ultra-Fine, BD Veo Insulin Syringe Ultra-Fine
BD Luer-Lok Syringe 1 ml	BD Insulin Syringe Ultra-Fine, BD Veo Insulin Syringe Ultra-Fine
BD SafetyGlide Insulin Syringe 1 ml 29 gauge x 1/2"	BD Insulin Syringe Ultra-Fine, BD Veo Insulin Syringe Ultra-Fine
Carbamazepine ER 100 mg cap	Carbamazepine ER tablet, extended release, 12 hour, gabapentin capsule, lamotrigine tablet
Carbamazepine ER 200 mg cap	Carbamazepine ER tablet, extended release, 12 hour, gabapentin capsule, lamotrigine tablet

Impacted Medicine	Alternative Medicine
Carbamazepine ER 300 mg cap	Carbamazepine ER tablet, extended release, 12 hour, gabapentin capsule, lamotrigine tablet
Clonazepam 0.125 mg odt	Alprazolam tablet, lorazepam tablet, clonazepam tablet
Clonazepam 0.25 mg odt	Alprazolam tablet, lorazepam tablet, clonazepam tablet
Clonazepam 0.5 mg odt	Alprazolam tablet, lorazepam tablet, clonazepam tablet
Clonazepam 1 mg odt	Alprazolam tablet, lorazepam tablet, clonazepam tablet
Clonazepam 2 mg odt	Alprazolam tablet, lorazepam tablet, clonazepam tablet
Colestipol hcl 1 gm tablet	Cholestyramine light oral powder, cholestyramine (with sugar) oral powder
Colestipol hcl granules	Cholestyramine light oral powder, cholestyramine (with sugar) oral powder
Colestipol hcl granules packet	Cholestyramine light oral powder, cholestyramine (with sugar) oral powder
Cyclophosphamide 25 mg tablet	Cyclophosphamide 25 mg capsule, cyclophosphamide 50 mg capsule
Cyclophosphamide 50 mg tablet	Cyclophosphamide 25 mg capsule, cyclophosphamide 50 mg capsule
Cystadane 1 gm/scoop oral powder	Betaine oral powder
Demeclocycline 150 mg tablet	Minocycline capsule, doxycycline hyclate capsule
Demeclocycline 300 mg table	Minocycline capsule, doxycycline hyclate capsule
Desloratadine 5 mg tablet	Cetirizine tablet, levocetirizine tablet, fluticasone propionate nasal spray, suspension
Diclofenac pot 50 mg tablet	Meloxicam tablet, ibuprofen tablet, naproxen tablet
Diclofenac sod er 100 mg tab	Meloxicam tablet, ibuprofen tablet, naproxen tablet
Doxycycline mono 75 mg tablet	Doxycycline hyclate capsule, doxycycline hyclate 20 mg tablet, minocycline capsule
Emtriva 200 mg capsule	Emtricitabine capsule
Farydak 10 mg capsule	Consult your physician
Farydak 15 mg capsule	Consult your physician
Farydak 20 mg capsule	Consult your physician
Fentanyl 37.5 mcg/hr patch	Fentanyl 12 mcg/hr transdermal patch, Fentanyl 25 mcg/hr transdermal patch, Fentanyl 50 mcg/hr transdermal patch
Fentanyl 62.5 mcg/hr patch	Fentanyl 12 mcg/hr transdermal patch, Fentanyl 25 mcg/hr transdermal patch, Fentanyl 50 mcg/hr transdermal patch
Fentanyl 87.5 mcg/hr patch	Fentanyl 12 mcg/hr transdermal patch, Fentanyl 25 mcg/hr transdermal patch, Fentanyl 50 mcg/hr transdermal patch
Guanfacine 1 mg tablet	Clonidine HCl tablet
Guanfacine 2 mg tablet	Clonidine HCl tablet

Impacted Medicine	Alternative Medicine
Intelence 100 mg tablet	Etravirine tablet
Intelence 200 mg tablet	Etravirine tablet
Intelence 25 mg tablet	Etravirine tablet
Isradipine 2.5 mg capsule	Amlodipine tablet, nifedipine ER tablet, extended release, felodipine ER tablet, extended release 24 hour
Isradipine 5 mg capsule	Amlodipine tablet, nifedipine ER tablet, extended release, felodipine ER tablet, extended release 24 hour
Jynarque 15 mg (AM)/15 mg (PM) tablets	Consult your physician
Jynarque 15 mg tablet	Consult your physician
Jynarque 30 mg (AM)/15 mg (PM) tablets	Consult your physician
Jynarque 30 mg tablet	Consult your physician
Jynarque 45 mg (AM)/15 mg (PM) tablets	Consult your physician
Jynarque 60 mg (AM)/30 mg (PM) tablets	Consult your physician
Jynarque 90 mg (AM)/30 mg (PM) tablets	Consult your physician
Ketoprofen 25 mg capsule	Meloxicam tablet, ibuprofen tablet, naproxen tablet
Lamivudine hbv 100 mg tablet	Lamivudine 10 mg/mL oral solution, lamivudine 150 mg tablet, lamivudine 300 mg tablet
Levetiracetam ER 500 mg tablet	Levetiracetam tablet, lamotrigine tablet, gabapentin capsule
Levetiracetam ER 750 mg tablet	Levetiracetam tablet, lamotrigine tablet, gabapentin capsule
Levofloxacin 0.5% eye drops	Ciprofloxacin eye drops, moxifloxacin eye drops, ofloxacin eye drops
Nexavar 200 mg tablet	Sorafenib tablet
Niacin 500 mg tablet	Gemfibrozil tablet, ezetimibe tablet, fenofibrate micronized 134 mg capsule
Nizatidine 15 mg/ml solution	Famotidine tablet, cimetidine tablet
Nizatidine 150 mg capsule	Famotidine tablet, cimetidine tablet
Nizatidine 300 mg capsule	Famotidine tablet, cimetidine tablet
Oxybutynin 2.5 mg tablet	Oxybutynin chloride ER tablet, extended release 24 hour, oxybutynin chloride 5mg tablet, solifenacin tablet
Pindolol 10 mg tablet	Propranolol tablet, metoprolol tartrate tablet, metoprolol succinate ER tablet, extended release 24 hour
Pindolol 5 mg tablet	Propranolol tablet, metoprolol tartrate tablet, metoprolol succinate ER tablet, extended release 24 hour
Praziquantel 600 mg tablet	Consult your physician
Prednisolone 5 mg/5 ml soln	Prednisolone oral solution, prednisone oral solution, dexamethasone oral solution

Impacted Medicine	Alternative Medicine
Prednisolone sod ph 25 mg/5 ml	Prednisolone oral solution, prednisone oral solution, dexamethasone oral solution
Remdesivir 100 mg/20 ml (emergency use authorization)	Consult your physician
Revlimid 10 mg capsule	Lenalidomide capsule
Revlimid 15 mg capsule	Lenalidomide capsule
Revlimid 2.5 mg capsule	Lenalidomide capsule
Revlimid 20 mg capsule	Lenalidomide capsule
Revlimid 25 mg capsule	Lenalidomide capsule
Revlimid 5 mg capsule	Lenalidomide capsule
Sildenafil 10 mg/ml oral susp	Sildenafil (pulmonary hypertension) tablet, tadalafil (pulmonary hypertension) tablet, ambrisentan tablet
Sulindac 150 mg tablet	Meloxicam tablet, ibuprofen tablet, naproxen tablet
Sulindac 200 mg tablet	Meloxicam tablet, ibuprofen tablet, naproxen tablet
Sumatriptan 4 mg/0.5 ml cart	Sumatriptan subcutaneous syringe, sumatriptan tablet, naratriptan tablet
Sumatriptan 4 mg/0.5 ml inject	Sumatriptan subcutaneous syringe, sumatriptan tablet, naratriptan tablet
Sumatriptan 6 mg/0.5 ml cart	Sumatriptan subcutaneous syringe, sumatriptan tablet, naratriptan tablet
Sumatriptan 6 mg/0.5 ml vial	Sumatriptan subcutaneous syringe, sumatriptan tablet, naratriptan tablet
Sumatriptan 6 mg/0.5ml autoinj	Sumatriptan subcutaneous syringe, sumatriptan tablet, naratriptan tablet
Timolol 0.25% gel-solution	Timolol maleate eye drops, levobunolol eye drops, carteolol eye drops
Timolol 0.5% gel-solution	Timolol maleate eye drops, levobunolol eye drops, carteolol eye drops
Trizivir 300 mg-150 mg-300 mg tablet	Consult your physician
Trulicity 0.75 mg/0.5 ml subcutaneous pen injector	Ozempic subcutaneous pen injector, Rybelsus tablet
Trulicity 1.5 mg/0.5 ml subcutaneous pen injector	Ozempic subcutaneous pen injector, Rybelsus tablet
Trulicity 3 mg/0.5 ml subcutaneous pen injector	Ozempic subcutaneous pen injector, Rybelsus tablet
Trulicity 4.5 mg/0.5 ml subcutaneous pen injector	Ozempic subcutaneous pen injector, Rybelsus tablet
Tyvaso 1.74 mg/2.9 ml (0.6 mg/ml) solution for nebulization	Consult your physician

Impacted Medicine	Alternative Medicine
Tyvaso Institutional Starter Kit 1.74 mg/2.9 mL soln for nebulization	Consult your physician
Tyvaso Refill Kit 1.74 mg/2.9 mL (0.6 mg/mL) solution for nebulization	
Tyvaso Starter Kit 1.74 mg/2.9 mL solution for nebulization	Consult your physician
V-GO 20 device	Omnipod 5 G6 Pods (Gen 5) subcutaneous cartridge Omnipod Classic Pods (Gen 3) subcutaneous cartridge, Omnipod Dash Pods (Gen 4) subcutaneous cartridge, Omnipod DASH PDM Kit (Gen 4), Omnipod 5 G6 Intro Kit (Gen 5) subcutaneous cartridge with controller, Omnipod 5 G6 Pods (Gen 5) subcutaneous cartridge
V-GO 30 device	Omnipod 5 G6 Pods (Gen 5) subcutaneous cartridge Omnipod Classic Pods (Gen 3) subcutaneous cartridge, Omnipod Dash Pods (Gen 4) subcutaneous cartridge, Omnipod DASH PDM Kit (Gen 4), Omnipod 5 G6 Intro Kit (Gen 5) subcutaneous cartridge with controller, Omnipod 5 G6 Pods (Gen 5) subcutaneous cartridge
V-GO 40 device	Omnipod 5 G6 Pods (Gen 5) subcutaneous cartridge Omnipod Classic Pods (Gen 3) subcutaneous cartridge, Omnipod Dash Pods (Gen 4) subcutaneous cartridge, Omnipod DASH PDM Kit (Gen 4), Omnipod 5 G6 Intro Kit (Gen 5) subcutaneous cartridge with controller, Omnipod 5 G6 Pods (Gen 5) subcutaneous cartridge
Votrient 200 mg tablet	Consult your physician
WesNatal DHA Complete 29 mg iron-1 mg-200 mg oral pack	Folivane-OB capsule, Complete Natal DHA oral pack
Xtampza ER 13.5 mg capsule sprinkle	Morphine ER tablet, extended release, hydrocodone bitartrate ER tablet, crush resist, extended release 24 hour
Xtampza ER 18 mg capsule sprinkle	Morphine ER tablet, extended release, hydrocodone bitartrate ER tablet, crush resist, extended release 24 hour
Xtampza ER 27 mg capsule sprinkle	Morphine ER tablet, extended release, hydrocodone bitartrate ER tablet, crush resist, extended release 24 hour
Xtampza ER 36 mg capsule sprinkle	Morphine ER tablet, extended release, hydrocodone bitartrate ER tablet, crush resist, extended release 24 hour
Xtampza ER 9 mg capsule sprinkle	Morphine ER tablet, extended release, hydrocodone bitartrate ER tablet, crush resist, extended release 24 hour



Updates made to the 2024 medication preauthorization and notification list

Humana's PT committee establishes and maintains the preauthorization list (PAL). The committee met in July 2023 and approved PAL changes, effective Jan. 1, 2024. Members are notified of negative changes at least 30 days before the effective date. **View the updated PAL by clicking here.**

Brand name	Generic name	Billing code	Chnagne type
Amondys-45	Casimersen	J1426	PAL Addition
Cosela	Trilaciclib	J1448	PAL Addition
Defitelio	Defibrotide sodium	C9399, J3490	PAL Addition
Evkeeza	Evinacumab-dgnb	J1305	PAL Addition
Herceptin Hylecta	Trastuzumab and hyaluronidase-oysk	J9356	PAL Addition
Jemperli	D-gxly	J9272	PAL Addition
Kogenate FS	Antihemophilic factor [recombinant]	J7192	PAL Addition
Nulibry	Fosdenopterin	C9399, J3490	PAL Addition
Margenza	Margetuximab-cmkb	J9353	PAL Addition
Monjuvi	Tafasitamab-cxix	J9349	PAL Addition
Oxlumo	Lumasiran	J0224	PAL Addition
Phesgo	Pertuzumab, trastuzumab, and hyaluronidase-zzxf	J9316	PAL Addition
Recombinate	Antihemophilic factor [recombinant]	J7192	PAL Addition
Riabni	Rituximab-arrx	Q5123	PAL Addition
Romidepsin	Romidepsin	J9318, J9319	PAL Addition
Scenesse	Afamelanotide	J7352	PAL Addition
Sinuva	Mometasone furoate	J7402	PAL Addition
Tegsedi	Inotersen	J3490, C9399	PAL Addition
Viltepso	Viltolarsen	J1427	PAL Addition
Xofigo	Radium Ra 223 dichloride	A9606	PAL Addition
Zynlonta	Loncastuximab tesirine-lpyl	J9359	PAL Addition



Concurrent clinical safety alerts help pharmacies see potential risks before dispensing

As a part of our enterprise-wide opioid strategy, Humana Healthy Horizons® implemented concurrent reviews or safety alerts at the point of service to help pharmacies identify and address potentially inappropriate or unsafe drug therapy before dispensing. Your patients may experience medication claims rejections at their pharmacy if impacted. For further details on Humana Healthy Horizons' point-of-sale safety updates, please visit the **2024 Humana pharmacy point-of-sale safety edits webpage**.



Retrospective drug utilization review helps pharmacies safely dispense prescriptions

Humana Healthy Horizons' Retrospective Drug Utilization Review Program supports you in the care of your patients through regular reviews of pharmacy claims data to help detect potentially adverse utilization patterns. You may receive subsequent intervention recommendations via direct mail or fax to alert you to important drug safety issues for your patients. Examples of campaigns include:

- Asthma inhaled therapy: Prescribers of patients younger than 12 years with an asthma diagnosis who may be receiving an inhaled corticosteroid without a short-acting bronchodilator may be notified.
- Concurrent opioid and gabapentinoid utilizers: Prescribers of patients with claims for concurrent opioid and high-dose gabapentinoid therapy (gabapentin dose more than 900 mg/day or pregabalin dose more than 450 mg/day) may be notified.



Enhanced vaccine coverage on the pharmacy benefit

In compliance with Centers for Medicare and Medicaid Services guidance, the formulary was updated with coverage of all Advisory Committee on Immunization Practices-recommended vaccines for adults over age 19. Eligible members can receive eligible vaccines with a \$0 copay at the pharmacy. Vaccines in scope for this coverage update are indicated for the following vaccine-preventable diseases: tetanus and pertussis; hepatitis A; hepatitis B; Haemophilus influenzae; human papilloma virus (HPV); measles, mumps, and rubella; meningitis; respiratory syncytial virus; and varicella. Vaccines for COVID-19, influenza, pneumonia, and shingles (herpes zoster) will continue to be covered. A list of all covered vaccines can be found on the **South Carolina Medicaid Preferred Drug List**.



Encourage patients to get HPV vaccine and reduce cancer risk

Strong and consistent vaccine recommendations can improve uptake. The HPV vaccine can be given as early as age 9 and prevents 6 types of cancers in both men and women. **HPV vaccines for adults 19-45 are covered by South Carolina Department of Health and**

Human Services.

Offer the HPV vaccine in the same way you would offer other vaccines to improve compliance. For more information, visit the resources below:

Practicing Conversations with HPV Vaccine: Same Way Same Day™ | American Academy of Pediatrics (AAP) →

Talking to Parents About HPV Vaccine →



COVID-19 at-home test, treatment and vaccine coverage

Humana Healthy Horizons covers all at-home COVID-19 testing kits. These tests can be administered by the patient to detect current COVID-19 infections. At-home tests do not detect COVID-19 antibodies or previous infections. Members have a \$0 copay on these at-home testing kits.

The U.S. Food and Drug Administration (FDA) authorized certain antiviral medications and monoclonal antibodies to treat mild to moderate COVID-19 in people who are more likely to get very sick. Pharmacists have been granted the ability to prescribe Paxlovid to certain patients under emergency use authorization. Members have a \$0 copay on these treatments.

The FDA granted approval for the following antiviral COVID-19 treatments:

- Paxlovid (nirmatrelvir/ritonavir) for people 18 years and older (oral)
- Veklury (remdesivir) for people 28 days and older (intravenous infusion)

The FDA granted emergency use authorization for the following antiviral COVID-19 treatments:

- Paxlovid (nirmatrelvir/ritonavir) for people 12 years and older (oral)
- Lagevrio (molnupiravir) for people 18 years and older (oral)

According to the Centers for Disease Control and Prevention (CDC), COVID-19 vaccination is recommended for all people 6 months and older, including people who are pregnant, breastfeeding, trying to get pregnant or might become pregnant.

The FDA granted full use authorization for the following COVID-19 vaccines:

- Comirnaty (Pfizer-BioNTech) 2023-24 COVID vaccine for people 12 years and older
- Spikevax (Moderna) 2023-24 COVID vaccine for people 12 years and older

The FDA granted emergency use authorization for the following COVID-19 vaccines:

- Pfizer-BioNTech COVID-19 vaccine for people 6 months through 11 years old
- Moderna 2023-24 COVID vaccine for people 6 months through 11 years old
- Novavax 2023-24 COVID vaccine for people 12 years and older

As a reminder, members can obtain their COVID vaccine at any network pharmacy or provider. At this time, Humana Healthy Horizons does not prefer one vaccine product over another. Please encourage members 6 months and older to get vaccinated. While cases of myocarditis and pericarditis in adolescents and young adults have been reported more often after getting the second dose than after the first dose of the Pfizer-BioNTech

and Moderna vaccines, these reports are rare, and the known and potential benefits of vaccination outweigh the known and potential risks. You can locate more information and learn how to report adverse events at the CDC page **Myocarditis and Pericarditis After mRNA COVID-19 Vaccination**.



Advise members with diabetes to use preferred blood glucose meters and strips

The preferred blood glucose meters and strips of Humana Healthy Horizons in South Carolina are True Metrix Meter and corresponding testing strips manufactured by Trividia. Members who currently use nonpreferred meters and strips will need a new prescription for True Metrix blood glucose meter and test strips. The test strips used with their old meter cannot be used with the new meter.

Members can visit [Trividiahealth.com](https://www.trividiahealth.com) to view training videos or call Trividia Customer Care at **800-803-6025** to learn more about using their new blood glucose meter.



Continuous blood glucose monitors reimbursable on the pharmacy benefit

Select continuous blood glucose monitors (CGM) readers and sensors are billable on the pharmacy benefit as of Jan. 1, 2024. Preferred CGM readers and sensors are Freestyle Libre and Dexcom G6 and G7. These products are covered without need for a prior authorization.



Diabetes HEDIS measures help track quality care for affected members

According to the CDC, diabetes is the most expensive chronic condition in our nation, with \$1 out of every \$4 in US healthcare costs spent caring for people with diabetes.¹

Some more numbers:

- \$237 billion is spent each year on direct medical costs and \$90 billion on reduced productivity.¹
- 48%-64% of lifetime medical costs for a person with diabetes are complications related to diabetes, such as heart disease and stroke.¹

Through its accreditation with the **National Committee for Quality Assurance (NCQA)**, Humana strives to improve healthcare quality and measurement. To prevent complications in people living with diabetes, enhance their quality of life and improve clinical outcomes, Humana measures clinical performance and consumer experience using Health Effectiveness Data and Information Set (HEDIS) and Consumer Assessment of Healthcare Providers and Systems (CAHPS) data. These data are used to analyze gaps and guide improvement interventions.

The following are HEDIS measures that relate to diabetic patient care:

1. Hemoglobin A1c control goal for patients with diabetes (HBD) members 18-75 years old:

Goal: HbA1C less than 8% (most recent of measurement year)

2. Blood pressure control goal for patients with diabetes (BPD) members 18-75 years old:
Goal: less than 140/90 mm Hg (most recent of measurement year)
3. Eye exam goal for patients with diabetes (EED) members 18-75 years old: Goal: diabetic retinal eye exam
4. Kidney health evaluation goal for patients with diabetes (KED) members 18-85 years old: Goal: kidney health evaluation (complete eGFR and uACR)
5. Statin therapy goal for patients with diabetes (SPD) members 40-75 years old (who do not have ASCVD): Goal: Receive statin therapy (members who were dispensed at least one statin medication of any intensity during the measurement year) and have a statin adherence rate of 80% (members who remain on statin medication of any intensity for at least 80% of treatment period)

Pharmacists can be instrumental in helping patients manage diabetes by offering ongoing education on lifestyle changes, medications and disease state management. They also act as drug therapy experts, encourage medication compliance and provide medication reconciliation following hospital admission. When diabetes is well controlled, long-term complications can be prevented.



Copayments for certain medications may be waived

The prescription copayment is \$3.40 per prescription/refill if a member is subject to a copayment. Copayments for certain medications and certain individuals may be waived. Prescription copayments are processed as follows:

- Beneficiaries receiving antibiotic prescriptions for the following sexually transmitted infections are exempt from the collection of the \$3.40 copayment:
 - Syphilis, chlamydia, gonorrhea, herpes, candidiasis and trichomoniasis
- For the above to process at \$0 copay:
 - The prescriber must write the International Classification of Diseases, 10th Revision (ICD-10) diagnosis code on the prescription for the STI treatment for the medication to be considered for reimbursement by Medicaid.
 - The pharmacy must enter the ICD-10 diagnosis code at the point of sale.

If you have trouble entering the ICD-10 code, please contact SS&C Health via one of the following methods:

- Email the help desk at help@argushealth.com.
- Call the help desk at **816-435-2231** or **800-792-7487**, ext. **52231**.

To improve maternal and birth outcomes, Humana Healthy Horizons in South Carolina supports our pregnant population with the pharmacy co-pay exclusion.

- To qualify, members should report their pregnancy to **SCDHHS**. Members may call **888-549-0820** to update their pregnancy status.
- Members receiving diabetic supplies are also exempt from the collection of the



\$3.40 copayment.

Humana Healthy Horizons evaluates utilization trends and new drug therapies to improve the health of members

Humana Healthy Horizons monitors trends in utilization and new drug therapies as they come to market. Prior authorization and coverage are determined after evaluation using industry proven clinical resources, including FDA approval information, peer-reviewed medical literature, evidence-based effectiveness studies and clinical practice guidelines. Then we create evidence-based formularies or PDLs and utilization management requirements, including prior authorization, quantity limits and step therapies.

To learn more, visit the [medical and pharmacy coverage policies webpage](#).



Utilization management initiatives highlight a holistic approach to therapeutic class drug evaluations

Humana Healthy Horizons performs a holistic clinical evaluation of every therapeutic class when reviewing our PDL for the next year. The following are a few examples of our therapeutic class evaluations:

- We added expanded access for dosage forms that may benefit pediatric patients.
- We added oral option Rybelsus for diabetic patients unable or unwilling to use injectable products, while maintaining existing coverage for the injectables.
 - Trulicity and Ozempic injectables have the majority of patients.
 - Humana strives to minimize displacing members off their current therapies whenever possible to ensure a positive member experience.
- During evaluation of inhaled corticosteroids for asthma treatment, we noticed a lack of migration to a preferred product, Arnuity Ellipta, in the current year.
 - Fluticasone propionate HFA, the authorized generic product for Flovent HFA, has replaced Arnuity Ellipta with minimal impact to patients.
 - Educating the provider that the generic product meets treatment needs, along with Humana's quick response for inclusion of the generic to the 2023 PDL, met the prescribing needs and bridged the gap of generic product availability.



Improve care and reduce costs through our specialty medication programs

Humana Healthy Horizons has several specialty programs that promote high-quality care and decrease costs of specialty medications for our members. Our multidisciplinary taskforce uses a team of associates to influence specialty medication utilization for rare diseases via thorough case review.

The goal is to improve patient outcomes and mitigate spending. Smart maintenance dose is a point-of-sale edit for specialty medications with a higher loading dose and lower



maintenance dose that rejects claims in excess of the recommended maintenance dose once the loading dose is fulfilled.

Prescribe covered drugs quickly with our common PDL quick reference

The pharmacy team develops and maintains a reference document called the Common PDL. This quick reference was developed for both prescribers and our internal care teams to outline the most prescribed medications along with less expensive alternatives for our Medicaid population. The Common PDL is updated as needed to align with Humana's preferred drug list changes.



Find our preauthorization and notification list for healthcare providers online

The preauthorization and notification list (PAL) describes services and medications that are commonly reviewed and may require additional clinical information. Medications include those delivered in the physician's office, clinic, outpatient or home setting.



Look for general pharmacy news on our pharmacy news website

Find pharmacy-related safety alerts, drug recalls, new generic drug announcements and other medication information on the pharmacy news webpage.

References:

1. "The Health and Economic Benefits of Diabetes Interventions," Centers for Disease Control and Prevention, last accessed Feb. 2, 2024, <http://www.cdc.gov/chronicdisease/programs-impact/pop/diabetes.htm>.